Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.
Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.